South Carolina Attorney General Alan Wilson announced last month that settlement had finally been reached with Ortho-McNeil-Janssen Pharmaceuticals in the state’s Risperdal case, ending a nine-year-long legal battle.
The end came when the U.S. Supreme Court denied Janssen’s attempt to get a $124 million Risperdal verdict overturned, and the company’s final hope for appeal was exhausted on January 12, 2016.
The case involved claims that the Risperdal maker had used aggressive marketing techniques to market the anti-psychotic drug to doctors, in an effort to persuade them to prescribe the drug to their patients.
Janssen allegedly sent more than 7,000 letters overstating the efficacy of Risperdal to doctors, according to court documents.
South Carolina initially filed the Risperdal complaint in 2007, pursuing civil penalties on two different claims of illegal marketing practices:
When the state of South Carolina won the verdict in 2011, Janssen was ordered to pay $327 million in damages, or a $300 fine for every sample box of Risperdal that was distributed and a $4,000 fine per copy of the letter sent to prescribing physicians.
Janssen has been fighting the verdict in the case brought by the state of South Carolina since 2011, and in February 2015, the penalty was reduced to $136 million.
Less than six months later, in July 2015, the South Carolina Supreme Court reduced the penalty even further, this time to $124 million.
The justices explained that the need for a reduction was due to a recalculation of the original assessment.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.